Beside these, it is worth mentioning that a potent sirtuin inhibitor known as selisistat especially targeted at SIRT1 while with moderately inhibiting effect on SIRT2/3/6 and no effect on SIRT5 has entered a clinical trial for HD treatment, which exerts positive results in early stage HD patients[162]. The gene discussed is SIRT2; the disease is Huntington disease.